Timing correction: Although the prompt says “tomorrow,” August 6, 2026 is today. Zoetis is scheduled to report 2Q26 results and host its conference call at 8:30 a.m. ET on Thursday, August 6.
This is primarily a proof-of-stabilization quarter for Zoetis—not simply an EPS-beat quarter.
The central question is whether the sharp deterioration in U.S. companion-animal demand seen in 1Q has stopped getting worse. After 1Q, management reset expectations for a more price-sensitive pet owner, softer veterinary-clinic traffic, aggressive competition in dermatology and parasiticides, generic pressure on certain legacy brands, and distributor/retail replenishment headwinds. The stock has already repriced severely: it closed at $74.41 on August 5, down roughly 41% year-to-date and about 33% from the pre-1Q-results close.
That creates a low bar, but not an easy one. A modest beat is unlikely to be enough if the result points to another leg down in U.S. companion animal sales, continued Librela erosion, or another reduction in 2026 guidance. Conversely, evidence that channel inventory has normalized, key franchises are sequentially stabilizing, and the full-year guide is intact could support a meaningful relief rally.
The available pre-earnings consensus calls for:
Those expectations reflect a much more cautious setup following the 1Q miss and guidance reset. The more important debate is likely around the quality of revenue, product-level trends, and management’s outlook rather than the headline EPS number.
In 1Q26, Zoetis reported:
| Metric | 1Q26 result |
|---|---|
| Revenue | $2.262B, +3% reported |
| Organic operational revenue | Flat |
| Adjusted EPS | $1.53, +9% reported |
| U.S. revenue | -8% operational |
| Global companion-animal revenue | -4% organic operational |
| Global livestock revenue | +12% organic operational |
The headline result understated the underlying weakness: management said roughly $100M of International revenue shifted into 1Q because of fiscal-year alignment and order/price-increase timing. Excluding that benefit, company-wide organic operational revenue would have declined about 5%.
The biggest pressure was U.S. companion animal, where sales declined 11%. The drivers were:
For 2Q, investors need confirmation that these were largely first-quarter-specific channel effects rather than a continuing structural reset in the U.S. pet-health market.
This is the key swing factor. In 1Q, U.S. companion-animal sales were $865M, down 11% year over year.
Investors should focus less on whether this business returns immediately to growth and more on whether the year-over-year decline narrows materially. Management had said channel inventory exited 1Q at the low end of its normalized range and did not embed a restocking assumption in guidance. That means another major channel-driven shortfall would be especially concerning.
Constructive outcome: A substantially smaller decline, stable distributor behavior, and commentary that vet traffic or prescription demand is no longer deteriorating.
Negative outcome: Another double-digit decline, additional pressure from retail-script denials, or evidence that promotions remain ineffective against lower-priced competition.
Librela remains a major sentiment issue. In 1Q:
Management emphasized that U.S. Librela sales improved sequentially for the first time in six quarters and that veterinarian education, specialist engagement, and medical-confidence initiatives were beginning to help. However, investors will want tangible evidence in the numbers.
Key items to watch:
A continued sharp decline would reinforce concerns that the franchise is not merely stabilizing from a difficult base.
Zoetis’ high-margin companion-animal franchises are under the most scrutiny.
Dermatology: Key dermatology sales were $347M in 1Q, down 11%. Apoquel faced price-driven competitive pressure, while Cytopoint held up relatively better. Zoetis is leaning on its portfolio breadth and expects Cytopoint Plus to reinforce its position over time, but that is not an immediate 2Q fix.
Parasiticides: The global Simparica franchise generated $385M, down 1%: - Simparica Trio: $297M, down 1% - Simparica: $88M, down 3%
The favorable signal was that U.S. Simparica share had improved sequentially versus late 2025, with puppy share remaining strong. The unfavorable signal was a shrinking market: fewer clinic visits, softer flea/tick/heartworm activity, slower alternative-channel growth, and lower retail script approval rates.
The market will likely reward signs that share has stabilized even if category growth remains modest. It will be less forgiving if Zoetis has to increasingly use price to defend its franchises, as that could pressure both revenue quality and gross margin.
The bull case rests partly on the portfolio’s diversification.
Livestock grew 12% organically in 1Q, with broad strength across cattle, swine, poultry, and fish. Favorable producer economics, disease activity, improved product supply, seasonal promotion execution, and demand for protein productivity all supported growth.
Management’s 1Q outlook called for mid- to high-single-digit livestock growth for 2026. Confirmation of that trajectory would provide an important buffer against softer companion-animal trends.
Global companion-animal diagnostics grew 10% in 1Q, led by reference labs, chemistry and hematology, including Vetscan Opticell. This is strategically important: diagnostic spending appears more resilient than discretionary preventive and chronic-care spending. Continued double-digit—or near double-digit—diagnostics growth would support the argument that demand for veterinary care has shifted rather than broadly collapsed.
International revenue grew 10% organically in 1Q, but that figure included the approximately $100M fiscal-year-alignment timing benefit. Excluding it, International growth was effectively flat.
Accordingly, 2Q will offer a cleaner test of underlying International demand. Investors should watch:
After 1Q, Zoetis reduced 2026 guidance to:
| 2026 guidance issued in May | Range |
|---|---|
| Revenue | $9.68B–$9.96B |
| Organic operational revenue growth | 2%–5% |
| Adjusted net income | $2.87B–$2.95B |
| Adjusted EPS | $6.85–$7.00 |
| Adjusted cost of sales as % of revenue | Approximately 28.5% |
| Adjusted SG&A | $2.35B–$2.40B |
| Adjusted R&D | $735M–$745M |
The company attributed the ability to preserve earnings growth despite weaker revenue to a comprehensive cost and productivity program. In 1Q, it recorded $20M of employee-termination costs related to organizational refinements.
A key nuance is that the 2026 guide includes a fiscal-year-alignment benefit that management previously estimated at roughly 200–250 basis points of revenue growth. That support does not recur in 2027, making the durability of underlying demand especially important.
Zoetis reported 1Q adjusted gross margin of 71.8%, down only 10 basis points reported; excluding FX, gross margin improved 140 basis points. Cost discipline and manufacturing execution have been better than the topline result suggests.
For 2Q, investors should monitor:
On capital allocation, Zoetis had $1.8B remaining on its authorization as of March 31. The company also carries about $9.0B of long-term debt, following debt-funded buybacks and convertible-note issuance. Buybacks helped 1Q adjusted EPS growth, but they cannot substitute for a recovery in underlying companion-animal demand.
Zoetis expects to close the acquisition of Neogen’s animal-genomics business in the second half of 2026. Strategically, the deal strengthens its livestock genetics capabilities and adds data-enabled tools for producers. Near term, however, it is not the central earnings catalyst.
Questions to watch:
Zoetis enters 2Q with a low valuation and low expectations, but with little tolerance for evidence that the U.S. companion-animal downturn is still accelerating. The stock’s reaction should be driven by the answer to one question:
Are the core companion-animal franchises stabilizing fast enough for Zoetis to hold its 2026 outlook and rebuild confidence in a return to durable growth?
Livestock, diagnostics, international expansion, pipeline assets, and cost discipline give Zoetis meaningful buffers. But the investment case still depends on management demonstrating that U.S. pet-health pressure, competition, and channel disruption are cyclical and manageable—not a lasting impairment to the company’s premium growth and margin profile.
Sources reviewed: Zoetis 1Q26 earnings release, 1Q26 earnings-call transcript, 1Q26 Form 10-Q, Zoetis’s 2Q26 webcast announcement, recent market-news digest, and historical share-price data. This is an earnings preview, not investment advice.